Still all these limitations notwithstanding, we think that our study has clinical relevance as it demonstrates, in a time of limited economical resources, that the clinical utility of ITPA genotyping in HCV-1 patients receiving PR+TVR is limited at least in those with advanced fibrosis/cirrhosis, as it does not predict management of anemia nor development of grade 3 anemia during TVR therapy. This evidence concerns the gene ITPA and Cirrhosis.